Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?

Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a relatively novel class of drug for treating type 2 diabetes mellitus (T2DM) that inhibits glucose reabsorption in the renal proximal tubule to promote glycosuria and reduce blood glucose levels. SGLT2i has been clinically indicated for treatin...

Full description

Bibliographic Details
Main Authors: Dan Xu, Owain Chandler, Cleo Wee, Chau Ho, Jacquita S. Affandi, Daya Yang, Xinxue Liao, Wei Chen, Yanbing Li, Christopher Reid, Haipeng Xiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Medicine
Subjects:
SGLT2i inhibitor
primary prevention
cardioprotection
renoprotection
chronic diseases prevention
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.712671/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.712671/full

Similar Items